Beth Cronin1, Amy Bregar2, Christine Luis3, Steven Schechter4, Paul Disilvestro5, Latha Pisharodi6, C James Sung6, Christina Raker7, Melissa Clark8, Katina Robison5. 1. Department of Obstetrics and Gynecology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. Electronic address: bcronin@wihri.org. 2. Department of Obstetrics and Gynecology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. 3. Program in Women's Oncology, Division of Research, Department of Obstetrics and Gynecology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. 4. University Surgical Associates, Alpert Medical School of Brown University, Providence, RI 02905, United States. 5. Program in Women's Oncology, Department of Obstetrics and Gynecology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. 6. Department of Pathology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. 7. Division of Research, Department of Obstetrics and Gynecology, Women & Infants Hospital, Alpert Medical School of Brown University, Providence, RI 02905, United States. 8. Department of Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA 01605, United States.
Abstract
OBJECTIVE: To compare the prevalence of abnormal anal cytology, high-risk anal HPV and biopsy proven anal dysplasia among women with a history of lower genital tract malignancy compared to those with dysplasia. METHODS: A prospective cohort study was performed from December 2012 to February 2014 at outpatient clinics at an academic medical center. Women with a history of high-grade cervical, vulvar, or vaginal dysplasia, or malignancy were recruited. Anal cytology and HPV genotyping were performed. All women with abnormal anal cytology were referred for high-resolution anoscopy and biopsy. RESULTS: Sixty-seven women had a lower genital tract malignancy and 123 had a history of genital dysplasia. Average age in the malignancy group was 52.6years (range 27-86) versus 43.5years (range 21-81) in the dysplasia group (p<0.0002). Similar rates of anal dysplasia were seen in both groups, 12.99% (10 cases) in the malignancy group, versus 12.20% (15) in the dysplasia group (p=1.0). Six women in the malignancy group had anal intraepithelial neoplasia (AIN2+) compared to 2 in the dysplasia group (p=0.03). CONCLUSIONS: We found high rates of abnormal anal cytology and HPV in women with lower genital tract dysplasia and malignancy. We also found high rates of anal dysplasia in both groups with a trend towards increased rate in those women with history of genital malignancy. Since precancerous anal lesions are detectable and treatable, anal cancer screening may be potentially useful in both of these higher risk groups.
OBJECTIVE: To compare the prevalence of abnormal anal cytology, high-risk anal HPV and biopsy proven anal dysplasia among women with a history of lower genital tract malignancy compared to those with dysplasia. METHODS: A prospective cohort study was performed from December 2012 to February 2014 at outpatient clinics at an academic medical center. Women with a history of high-grade cervical, vulvar, or vaginal dysplasia, or malignancy were recruited. Anal cytology and HPV genotyping were performed. All women with abnormal anal cytology were referred for high-resolution anoscopy and biopsy. RESULTS: Sixty-seven women had a lower genital tract malignancy and 123 had a history of genital dysplasia. Average age in the malignancy group was 52.6years (range 27-86) versus 43.5years (range 21-81) in the dysplasia group (p<0.0002). Similar rates of anal dysplasia were seen in both groups, 12.99% (10 cases) in the malignancy group, versus 12.20% (15) in the dysplasia group (p=1.0). Six women in the malignancy group had anal intraepithelial neoplasia (AIN2+) compared to 2 in the dysplasia group (p=0.03). CONCLUSIONS: We found high rates of abnormal anal cytology and HPV in women with lower genital tract dysplasia and malignancy. We also found high rates of anal dysplasia in both groups with a trend towards increased rate in those women with history of genital malignancy. Since precancerous anal lesions are detectable and treatable, anal cancer screening may be potentially useful in both of these higher risk groups.
Authors: Janet R Daling; Margaret M Madeleine; Lisa Godefroy Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: Hugo De Vuyst; Gary M Clifford; Maria Claudia Nascimento; Margaret M Madeleine; Silvia Franceschi Journal: Int J Cancer Date: 2009-04-01 Impact factor: 7.396
Authors: Joël Fokom Domgue; Craig Messick; Andrea Milbourne; Ming Guo; Mila P Salcedo; Kristina R Dahlstrom; Elizabeth Y Chiao; Ashish A Deshmukh; Erich M Sturgis; Kathleen M Schmeler Journal: Gynecol Oncol Date: 2019-03-01 Impact factor: 5.482